Individualized drug response related to genetic variations of cytochrome P450 isoforms and other enzymes

Farmacia

Volumn 58, Issue 3, 2010, Pages 245-254

  Paveliu, Marian Sorin ^a   Bengea, Simona ^a   Paveliu, Fraga Silvia ^b  

^a TITU MAIORESCU UNIVERSITY   (Romania)

^b Health Civil Society Dr Paveliu   (Romania)

Author keywords

Cytochrome P450; Dose; Efficacy; Gene polymorphism; SNPs; Therapy

Indexed keywords

AMITRIPTYLINE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLOPIDOGREL; CODEINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PENBUTOLOL; PERPHENAZINE; PHENYTOIN; PROPRANOLOL; RISPERIDONE; THIORIDAZINE; TORASEMIDE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; WARFARIN; XENOBIOTIC AGENT;

ALLELE; BLEEDING; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; MYOPATHY; PHARMACOGENETICS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

EID: 77953898376     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Azuma J., Nonen S., Chronic heart failure: beta-blockers and pharmacogenetics, Eur J Clin Pharmacol. Jan. 2009,65(1), 3-17.
2. Beinema M., Brouwers J.R., Schalekamp T., Wilffert B., Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon, Thromb Haemost. Dec. 2008, 100(6), 1052-7.
3. Bijl M.J., Visser L.E., van Schaik R.H. et al, Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users, Clin Pharmacol Ther. Jan. 2009, 85(1), 45-50.
4. Caldwell M.D., Berg R.L., Zhang K.Q. et al., Evaluation of genetic factors for warfarin dose prediction, Clin Med Res., Mar. 2007, 5(1), 8-16.
5. Suciu M., The role of nitric oxide (NO) and statins in endothelial dysfunction and atherosclerosis, Farmacia, 2009, 57(2), 131-140.
6. Gardiner S.J., Begg E.J., Pharmacogenetics, drug-metabolizing enzymes, and clinical practice, Pharmacol Rev., Sep. 2006, 58(3), 521-90.
7. Gladding P., Webster M., Zeng I. et al, The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial, JACC Cardiovasc Interv. Dec. 2008, 1(6), 612-9.
8. Jain K.K., Basic technologies for developing personalized medicine in: Textbook of personalized medicine, Springer, 2009, 15-19.
9. Kaneko S., Gerasimova T., Butler W.M. et al, The Use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status, Exp Mol Pathol. Aug. 2002, 73(1), 61-6.
10. Keen-Kim D., Grody W.W., Richards C.S., Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip 400 and molecular biology workstation, Expert Rev Mol Diagn. May 2006, 6(3), 287-94.
11. rd, Momary K.M., Thienopyridines: Time for Personalized Therapy?, JACC Cardiovasc Interv. Dec. 2008, 1(6), 718-9.
12. Kivistö K.T., Niemi M., Schaeffeler E., et al, Lipid-lowering response to statins is affected by CYP3A5 polymorphism, Pharmacogenetics, Aug. 2004, 14(8), 523-5.
13. Li Y., Zhang D., Jin W. et al, Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin, J Clin Invest. Feb. 2006, 116(2), 506-11.
14. Mega J.L., Morrow D.A., Brown A., Cannon C.P., Sabatine M.S., Identification of genetic variants associated with response to statin therapy, Arterioscler Thromb Vasc Biol. Sep. 2009, 29(9), 1310-5.
15. Rebsamen M.C., Desmeules J., Daali Y. et al, The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction, Pharmacogenomics J. Feb. 2009, 9(1), 34-41.
16. Rossi J.S., McLeod H.L., The pharmacogenetics of statin therapy: when the body aches, the mind will follow, J Am Coll Cardiol. Oct. 2009, 54(17), 1617-8.
17. SEARCH Collaborative Group, Link E., Parish S., Armitage J. et al, SLCO1B1 variants and statin-induced myopathy - a genomewide study, N Engl J Med. Aug. 2008, 359(8), 789-99.
18. Sherry S.T., Ward M., Sirotkin K., dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation, Genome Res Aug. 1999, 9(8), 677-9. (Pubitemid 29412785)
19. Sistonen J., Fuselli S., Palo J.U., Chauhan N., Padh H., Sajantila A., Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales, Pharmacogenet Genomics. Feb. 2009, 19(2), 170-9.
20. Smart A., Martin P., The promise of pharmacogenetics: assessing the prospects for disease and patient stratification, Stud Hist Philos Biol Biomed Sci., Sep. 2006, 37(3), 583-601.
21. Cucuiet S., Dogaru G., Bild V.N., Dogaru M.T., Modulation of tramadol antinociception by ketamine and baclofen in mice, Farmacia, 2008, 56(6), 675-691.
22. Stehle S., Kirchheiner J., Lazar A., Fuhr U., Pharmacogenetics of oral anticoagulants: a basis for dose individualization, Clin Pharmacokinet. 2008, 47(9), 565-94.
23. Voora D., Shah S.H., Spasojevic I. et al, The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J Am Coll Cardiol., Oct. 2009, 54(17), 1609-16.
24. Prasacu I., Mircioiu C., Sandulovici R., Enache F., Release of metoprolol from solid dosage forms. Choice and validation of theoretical model, Farmacia, 2009, 57(1), 89-98.
25. Ward M.B., Sorich M.J., McKinnon R.A., Cytochrome P450 Part 2: Genetics of Inter-Individual Variability. J Pharm Pract Res, 2008, 38, 226-9.